You are here

Walgreens, Rite Aid to Join to Create a Drugstore Giant

$9.4 billion acquisition comes as companies seek bargaining clout

Walgreens Boots Alliance Inc. has agreed to buy Rite Aid Corporation for about $9.4 billion, a move that would create a drugstore giant as companies across the U.S. health care industry look for ways to bulk up.

According to the Wall Street Journal (WSJ), Walgreens agreed to pay $9 a share in cash for Rite Aid, offering a 48% premium to Rite Aid’s closing price Monday. Rite Aid’s stock rose 43% to $8.67 on Tuesday after the WSJ reported on the merger talks. Walgreens shares rose 6.4% Tuesday to $95.16.

The deal, which would unite two of the country’s three biggest drugstore owners, would likely draw scrutiny from antitrust regulators, who could demand divestitures in exchange for their approval. It also adds to a blockbuster year for health care mergers and acquisitions, helping to put 2015 on track to be the busiest year ever for such deals. Including assumed debt, the transaction is valued at $17.2 billion. Rite Aid’s debt totaled $7.4 billion in August.

Drug makers, hospital chains, health insurers, and others have already struck some $427 billion of merger deals in the U.S. this year, according to Dealogic, as the Affordable Care Act and other factors spur them to seek more leverage with their suppliers and cut costs. By combining their drugstore networks, which together include roughly 13,000 U.S. stores, Walgreens and Rite Aid, which have both been pinched by drug-price inflation, could reap considerable savings.

Rite Aid, based in Camp Hill, Pennsylvania, has about 4,600 drugstores in 31 states. Walgreens has roughly 8,200 U.S. stores, while CVS Health Corporation has more than 7,800. Both Rite Aid and Walgreens have a major presence in states such as California, New York, and Massachusetts, while in others, including Florida, Texas, and Illinois, there isn’t any overlap. Walgreens and Rite Aid would be likely to argue to regulators that they compete not just with other traditional drugstore chains, but also with companies that sell groceries and with club stores.

In terms of market value, Rite Aid is much smaller than Walgreens and CVS, which both have market capitalizations of more than $100 billion. Rite Aid had revenue of $26.5 billion in the fiscal year ended in February. In the fiscal year ended in August 2014, Walgreens had revenue of $76.4 billion. CVS had 2014 sales of $139.4 billion.

Rite Aid, like its rivals, has sought to broaden its business lines to boost sales amid increased competition. The company has expanded its RediClinics, walk-in centers that can give flu shots and tend to ailments. It also has built a portfolio of 1,859 wellness stores, which offer organic food and natural personal-care products and which feature consultation rooms for discussions with pharmacists.

This year Rite Aid bought pharmacy benefit manager Envision Pharmaceutical Services, or EnvisionRx, for about $2 billion. Pharmacy benefit managers process prescriptions for the groups that pay for drugs, usually insurance companies or corporations, and use their size to negotiate better deals with drug makers and pharmacies. They often also operate mail-order pharmacies.

In September, Rite Aid cut its earnings outlook in part because of costs associated with the EnvisionRx deal. That had contributed to a nearly 20% reduction in Rite Aid’s share price this year before news of the Walgreens talks leaked. That decline might help explain the above-average share-price premium Walgreens is paying.

Walgreens is the product of acquisitions, giving it more than 13,200 stores in 11 countries. The company, based in Deerfield, Illinois, operates under the Walgreens and Duane Reade banners, and in the United Kingdom and elsewhere as Boots. It also has one of the largest pharmaceutical wholesale and distribution networks in the world. Walgreens was founded in 1901 when Charles R. Walgreen Sr. purchased the Chicago drugstore where he had worked as a pharmacist.

Source: Wall Street Journal, October 28, 2015.

Recent Headlines

Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs